Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olorofim + Caspofungin Prophylaxis in AML
NCT02856178Phase 2Withdrawn
- Sponsor
- F2G
- Start
- Apr 2017
- Primary completion
- Apr 2017
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of olorofim in invasive aspergillosis (IA), sponsored by F2G. Planned start Apr 2017; status: withdrawn.
02
Drugs
olorofim
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on NCT02856178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02856178.